+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention



Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention



Cardiovascular Revascularization Medicine 10(3): 144-150



High-sensitivity C-reactive protein (hs-CRP) elevation is associated with poor clinical outcome in patients with coronary artery disease (CAD). However, the prognostic value of preprocedural hs-CRP elevation before coronary stent implantation remains debated especially regarding restenosis and target vessel revascularization (TVR). Furthermore, whether hs-CRP elevation may predict stent thrombosis (ST) is unknown. We included 560 consecutive patients, who underwent coronary stent implantation in our institution. Blood samples for hs-CRP determination were obtained immediately before the procedure. During a median follow-up of 12.5 months, cardiovascular events including death, myocardial infarction (MI), TVR, and ST were systematically included. Median hs-CRP was 3.10 [25-75th percentile: 1.36-8.63] mg/l. There were 27 (4.8%) deaths, 17 (3.1%) nonfatal MI, 58 (10.5%) TVR, and 12 (2.1%) ST. The composite criteria death-MI occurred in 44 (7.9%) patients. Independent predictors of the composite death-MI were hs-CRP level [hazard ratio (HR)=1.33 (95% CI: 1.05-1.70); P=.021], diabetes (P=.003), and multivessel CAD (P=.011). The composite death-MI occurred in 31 (13.3%) of the 233 patients with hs-CRP >4.63 mg/l vs. 13 (4.0%) of the 327 patients with hs-CRP <4.63 mg/L (P<.001). By contrast, hs-CRP predicted neither TVR [HR=0.88 (0.73-1.08); P=.23] nor ST [HR=1.15 (0.77-1.71); P=.49]. High hs-CRP levels before coronary stent implantation are associated with risk of death or MI, but are not related to TVR or ST. These data suggest that preprocedural hs-CRP is more a predictor of global cardiovascular risk than a predictor of stent-related complications.

(PDF emailed within 0-6 h: $19.90)

Accession: 055139174

Download citation: RISBibTeXText

PMID: 19595394

DOI: 10.1016/j.carrev.2009.01.005


Related references

Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. American Journal of Cardiology 107(11): 1597-1603, 2011

Preprocedural High-Sensitivity C-Reactive Protein Predicts Long-Term Outcome of Percutaneous Coronary Intervention. Circulation Journal 81(1): 90-95, 2016

Weighing the risks of target vessel revascularization versus very late stent thrombosis in primary percutaneous coronary intervention. Jacc. Cardiovascular Interventions 5(10): 1052-1053, 2013

Increased rate of stent thrombosis and target lesion revascularization after filter protection in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: 15-month follow-up of the DEDICATION (Drug Elution and Distal Protection in ST Elevation Myocardial Infarction) trial. Journal of the American College of Cardiology 55(9): 867-871, 2010

Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent. American Journal of Cardiology 98(5): 616-618, 2006

Early Ventricular Tachycardia or Fibrillation in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention and Impact on Mortality and Stent Thrombosis (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial). American Journal of Cardiology 120(10): 1755-1760, 2017

Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. European Heart Journal 29(10): 1241-1249, 2007

Monocyte/HDL-cholesterol ratio predicts the definite stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Biomarkers in Medicine 9(10): 967-977, 2016

Preprocedural C-reactive protein is associated with death/myocardial infarction but not with repeat revascularization following PTCA. European Heart Journal 23(Abstract Supplement): 556, August-September, 2002

Interaction of diabetes and acute coronary syndromes in predicting death, myocardial infarction, and non-target lesion revascularization at 1-year follow up after percutaneous coronary intervention. Circulation 108(17 Supplement): IV-537, October 28, 2003

C-reactive protein predicts non-target lesion revascularization and cardiac events following percutaneous coronary intervention in patients with angina pectoris. Journal of Cardiology 53(3): 388-395, 2011

Abciximab reduces death and myocardial infarction but not target vessel revascularization in diabetics undergoing percutaneous transluminal coronary angioplasty The EPILOG experience. European Heart Journal 18(ABSTR SUPPL ): 13, 1997

Preprocedural C-reactive protein is not associated with angiographic restenosis or target lesion revascularization after coronary artery stent placement. Clinical Chemistry 50(9): 1589-1596, 2004

Impact of preprocedural high-sensitivity C-reactive protein on contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention. Angiology 65(5): 402-407, 2014

Prognostic Value of High-Sensitivity C-Reactive Protein and Lipoprotein a in Acute Myocardial Infarction Patients Receiving Emergency Percutaneous Coronary Intervention. Journal of Medical Biochemistry 31(2), 2012